Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$2.09 -5.9%	$2.77	$2.02 ▼ $4.75	$661.53M	0.5	2.46 million shs	3.14 million shs
COGT Cogent Biosciences	$5.33 -6.8%	$7.66	$5.30 ▼ $12.61	$606.82M	1.67	1.24 million shs	1.13 million shs
PRTA Prothena	$11.32 -6.8%	$14.11	$11.11 ▼ $25.42	$609.32M	-0.02	490,748 shs	456,544 shs
RTTR Ritter Pharmaceuticals	$3.41 -2.3%	$2.99	$0.15 ▼ $1.27	$157.38M	-0.43	14.23 million shs	81,317 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-5.86%	-11.44%	-10.68%	-33.23%	-52.28%
COGT Cogent Biosciences	-6.82%	-19.36%	-25.66%	-32.36%	-22.64%
PRTA Prothena	-6.75%	-12.99%	-24.83%	-18.39%	-53.34%
RTTR Ritter Pharmaceuticals	-2.29%	+2.71%	+10.00%	-18.84%	+712.10%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	1.9875 of 5 stars	3.3	1.0	0.0	0.0	1.4	3.3	0.6
COGT Cogent Biosciences	2.0777 of 5 stars	4.4	1.0	0.0	0.0	1.9	0.0	0.6
PRTA Prothena	3.1534 of 5 stars	4.4	1.0	0.0	0.0	2.6	3.3	0.6
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$7.00	234.93% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$14.43	170.70% Upside
PRTA Prothena	2.75	Moderate Buy	$55.00	385.87% Upside
RTTR Ritter Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RTTR, COGT, PRTA, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/7/2025	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	COGT Cogent Biosciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$17.00
3/3/2025	ABCL AbCellera Biologics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/28/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
2/27/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $8.00
2/26/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/26/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$94.00 ➝ $110.00
2/25/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$11.00
2/21/2025	PRTA Prothena	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $20.00
2/21/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
2/21/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $48.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	21.60	N/A	N/A	$3.97 per share	0.53
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$2.30 per share	N/A
PRTA Prothena	$135.16M	4.51	N/A	N/A	$10.46 per share	1.08
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	$0.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.40M	-$0.55	N/A	N/A	N/A	-533.32%	-15.73%	-12.22%	5/6/2025 (Estimated)
COGT Cogent Biosciences	-$192.41M	-$1.94	N/A	N/A	N/A	N/A	-112.55%	-60.44%	5/6/2025 (Estimated)
PRTA Prothena	-$147.03M	-$2.30	N/A	N/A	N/A	-90.50%	-22.67%	-19.68%	5/6/2025 (Estimated)
RTTR Ritter Pharmaceuticals	-$10.13M	N/A	N/A	∞	N/A	N/A	N/A	-162.05%	N/A

Latest RTTR, COGT, PRTA, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/20/2025	Q4 2024	PRTA Prothena	-$1.02	-$1.08	-$0.06	-$1.08	$7.53 million	$2.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	9.34	9.34
COGT Cogent Biosciences	N/A	6.44	6.44
PRTA Prothena	N/A	11.52	11.52
RTTR Ritter Pharmaceuticals	N/A	3.67	3.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
COGT Cogent Biosciences	N/A
PRTA Prothena	97.08%
RTTR Ritter Pharmaceuticals	0.84%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.00%
COGT Cogent Biosciences	5.92%
PRTA Prothena	28.20%
RTTR Ritter Pharmaceuticals	15.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	297.99 million	212.66 million	Optionable
COGT Cogent Biosciences	80	113.85 million	103.92 million	Optionable
PRTA Prothena	130	53.83 million	38.64 million	Optionable
RTTR Ritter Pharmaceuticals	7	46.15 million	N/A	Not Optionable

RTTR, COGT, PRTA, and ABCL Headlines

Recent News About These Companies

Rochester football bows to St. Louis Cardinal Ritter in battle of state champions

October 4, 2024 | sj-r.com

Scott Ritter claims search of home is related to 'foreign agent’ law

August 9, 2024 | timesunion.com

FBI raids NY home of ex-UN weapons inspector Scott Ritter

August 9, 2024 | nypost.com

John Ritter Biography & Movies

May 22, 2024 | tribute.ca

Jeff Ritter

April 19, 2024 | si.com

Dr. John D. Ritter

January 24, 2024 | health.usnews.com

German chocolate war ends with Ritter Sport victory

October 28, 2023 | politico.eu

Kristen Ritter

September 15, 2023 | health.usnews.com

Op-ed column: Sandusky sex charges contrast with setup against Scott Ritter

July 8, 2023 | dailygazette.com

Scott Ritter arrested in Pennsylvania on child sex charges

July 8, 2023 | dailygazette.com

Dr. Harold K. Ritter

July 8, 2023 | health.usnews.com

Denver Business Journal welcomes new tech reporter

July 1, 2023 | bizjournals.com

Gary W. Ritter, Ph.D.

June 16, 2023 | slu.edu

Jason Ritter and Drew Barrymore's raw conversation on her show may matter more than you think

April 10, 2023 | usatoday.com

Ritter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment

March 29, 2023 | thestreet.com

Global Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second Genome

March 18, 2023 | finance.yahoo.com

Melanie Lynskey's husband Jason Ritter will join her in Yellowjackets this season

January 19, 2023 | yahoo.com

Ritter Public Library in Vermilion adds book club

January 15, 2023 | morningjournal.com

Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsight

November 16, 2022 | finance.yahoo.com

Burlington freshman Olivia Ritter hits to pool as Olivia Kraus climbs out of the water

October 1, 2022 | thehawkeye.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RTTR, COGT, PRTA, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$2.09 -0.13 (-5.86%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$2.11 +0.02 (+1.15%)

As of 04/3/2025 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cogent Biosciences NASDAQ:COGT

$5.33 -0.39 (-6.82%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$5.36 +0.03 (+0.56%)

As of 04/3/2025 04:45 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Prothena NASDAQ:PRTA

$11.32 -0.82 (-6.75%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$11.32 +0.00 (+0.04%)

As of 04/3/2025 06:45 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Ritter Pharmaceuticals NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time